Could Intellipharmaceutics Internation (NASDAQ:IPCI) See a Reversal After Less Sellers Came In?

February 14, 2018 - By reb123z

 Could Intellipharmaceutics Internation (NASDAQ:IPCI) See a Reversal After Less Sellers Came In?

The stock of Intellipharmaceutics Internation (NASDAQ:IPCI) registered a decrease of 2.57% in short interest. IPCI’s total short interest was 1.39M shares in February as published by FINRA. Its down 2.57% from 1.42 million shares, reported previously. With 194,400 shares average volume, it will take short sellers 7 days to cover their IPCI’s short positions. The short interest to Intellipharmaceutics Internation’s float is 5.71%.

The stock decreased 2.82% or $0.0222 during the last trading session, reaching $0.7661. About 47,075 shares traded. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since February 14, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $26.53 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellipharmaceutics Intl had 6 analyst reports since December 31, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Tuesday, June 6. The rating was maintained by Maxim Group on Friday, June 30 with “Buy”. The firm has “Buy” rating given on Friday, July 21 by Maxim Group. Maxim Group maintained IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) on Thursday, December 31 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Monday, February 12 report.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: Marketwatch.com which released: “Intellipharmaceutics International Inc.” on July 27, 2017, also Streetinsider.com with their article: “Intellipharmaceutics (IPCI) Announced Completed Meetings with FDA Regarding …” published on February 09, 2018, Globenewswire.com published: “Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista …” on April 10, 2017. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: Globenewswire.com and their article: “Intellipharmaceutics Announces Closing of US$4 Million Financing” published on October 13, 2017 as well as Globenewswire.com‘s news article titled: “Intellipharmaceutics Receives Complete Response Letter from the FDA for …” with publication date: September 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.